FDA Clears Ameluz for Skin Cancer, a First for Photodynamic Therapy
BFRI has more than doubled off its 52-week low of $0.555 on elevated volume (2.9× avg).
Summary
Biofrontera received FDA approval for Ameluz to treat superficial basal cell carcinoma, the first PDT drug approved for skin cancer in the U.S. Launch is planned for late Q4 2026 through Q1 2027.
Key Events · Product Development and Regulatory · BFRI
-
FDA Approves Ameluz for sBCC
The FDA approved the supplemental New Drug Application for Ameluz in combination with the BF-RhodoLED lamp for superficial basal cell carcinoma in adults.
-
First-in-Class PDT for Skin Cancer
Ameluz becomes the first and only photodynamic therapy approved in the U.S. to treat a skin cancer, and the only topical PDT indicated for both actinic keratosis and skin cancer.
-
Phase 3 Efficacy Data
The pivotal trial showed 66% composite complete response with Ameluz PDT versus 5% with placebo; histological clearance was 76% versus 19%.
-
Market Expansion Opportunity
An estimated 540,000 to 720,000 superficial BCC cases occur annually in the U.S., representing a significant new addressable market for the existing commercial organization.
Analysis · BFRI · Life Sciences
The FDA has approved Ameluz for superficial basal cell carcinoma, making it the first and only photodynamic therapy cleared in the U.S. to treat a skin cancer. This label expansion opens an estimated 540,000 to 720,000 new cases annually and gives the company a differentiated, non-surgical option in medical dermatology. The approval arrives at a pivotal moment—the company disclosed a going concern warning in its last 10-Q—so this milestone is a meaningful step toward commercial viability and could accelerate adoption of its RhodoLED lamp platform.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.7% of the 383 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BFRI was trading at $1.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23M. The 52-week trading range was $0.55 to $1.66. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.